Role of sentinel lymph node biopsy in assessing the cancer spread to axilla in early breast cancer

Ashutosh Gumber; Manish Mudgal

doi:10.18203/2349-2902.isj20164445

Authors

Ashutosh Gumber Department of Surgery, Blackpool Teaching Hospitals NHS Foundation Trust, United Kingdom
Manish Mudgal Department of Surgery, MGS General Hospital, Surendranagar, Gujarat, India

DOI:

https://doi.org/10.18203/2349-2902.isj20164445

Keywords:

Axillary lymph node, Biopsy, Early breast cancer, Minimally invasive, Sentinel lymph node

Abstract

Background:Sentinel lymph node (SLN) biopsy is a minimally invasive alternative to axillary lymph node dissection as a way to stage breast cancer in clinically node-negative patients. Objective of the study was to determine the safety and reliability of sentinel lymph node biopsy without axillary lymph node dissection (ALND) in early breast cancer patients.

Methods: This prospective study was conducted in patients with operable breast cancer in a single surgical unit of our hospital. Patients with T1-T3 breast cancer with clinically negative axilla and patients with previous lumpectomy were included. All the patients had undergone complete axillary lymph node dissection after sentinel lymph node biopsy. All the specimens were sent separately for paraffin section histopathology.

Results:Mean age of 35 female patients included was 54 years. SLN was identified in 94.29% cases and it could not be identified in 2 cases. SLN (96.97%) was most commonly identified at level I. Mean numbers of sentinel node and axillary node were 1.52 and 16.11 respectively. Study of SLN biopsy with methylene blue dye for staging the axilla was done with 81.25% sensitivity and 100% specificity. Positive predictive value was 100% and was able to negatively predict the axilla in 86.36% with an overall accuracy of staging of 96.97% and false negative rate of 18.75%.

Conclusions:Sentinel lymph node biopsy without axillary lymph node dissection in sentinel lymph node negative breast cancers appears to be a safe and reliable procedure for determining the nodal status and ensuring the loco-regional control.

Metrics

Metrics Loading ...

References

Gajdos C, Tartter PI, Ira J, Bleiweiss IJ. Lymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with T1 breast cancers. Ann Surg. 1999;230(5):692.

Amersi F, Morton DL. The role of sentinel lymph node biopsy in the management of melanoma. Adv Surg. 2007;41:241-56.

Engel J, Kerr J, Raab AS, Sauer H, Holzel D. Axilla surgery severly affects quality of life: results of 5-year prospective study in breast cancer patients. Breast cancer Res Treat. 2003;79(1):47-7.

Kissen MW, Rovere G, Easton D, Westbury G. Risk of lymphedema following the treatment of breast cancer. Br J Surg. 1986;73(7):580-4.

Morton D, Cagle L, Wong J. Intraoperative lymphatic mapping and selective lymphadenectomy: technical details of a new procedure for clinical stage I melanoma. Journal Clinical Oncol. 1993;1:1751-6.

Alex JC, Weaver DL, Fairbank JT, Rankin BS, Krag DN. Gamma-probe-guided lymph node localization in malignant melanoma. Surg Oncol. 1993;2(5):303-8.

Gruliano AE, Kirgan, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220(3):391-401.

Rashid OM, Takabe K. Sentinel lymph node biopsy for breast cancer: our technique and future directions in lymph node staging. J Nucl Med Radiat Ther. 2012;2012(0):005.

Simmons RM, Smith SMR, Osborne MP. Methylene blue as an alternative to isosulfan blue for sentinel lymph node localization. Breast J. 2001;7(3):181-3.

Barnwell JM, Arredondo MA, Kollmorgen D, Gibbs JF, Lamonica D, Carson W. Sentinel node biopsy in breast cancer. Ann Surg Oncol. 1998;5:126-30.

Cox CE, Pendas S, Cox JM, Joseph E, Shons AR, Yeatman T et al. Guide lines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg. 1998;227(5):646-53.

Linehan DC, Hill AD, Akhurst T, Yeung H, Yeh SD, Tran KN et al. Intradermal radiocolloid and intraparenchymal blue dye injection optimise sentinel node identification In breast cancer patient Ann Surg Oncol. 1999;6:450-4.

Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, et al. The sentinel node in breast cancer a muticentre validation study. N Engl J Med. 1998;339:941-6.

Mcmasters KM, Tuttle TM, Carlson DJ, Brown CM, Noyes RD, Glaser RL, et al. Sentinel lymph node biopsy for breast cancer a suitable alternative to routine axillary dissection in multinstitutional practice when optimal technique is used. J Clin Oncol. 2000;18(13):2560-6.

Giuliano AE, Jones RC, Brannan M, Statman R. Sentinel lymphadenectomy In breast cancer. J Clin Oncol. 1997;16:2346-60.

Albo D, Wayne JD, Hunt KK, Rahlfs TF, Singletary SE, Ames FC et al. Anaphylactic reactions to isosulfane blue dye during sentinel lymph node biopsy for breast cancer. Am J Surg. 2001;182;393-8.

Laurie SA, Khan DA, Gruchalla RS, Peters G. Anaphylaxis to isosulfan blue. Ann Allergy Asthma Immunol. 2002;88:64-6.

Borgstein PJ, Pikers R, Comans EF, Diest PJ, Boom RP, Meijer S. Sentinel lymph node biopsy in breast cancer Guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg. 1998;186(3):275-83.

Veronesi U, Paganclli G, Galimborti V, Viale G, Zurrida S, Bedoni M et al. Sentinel node biopsy to avoid axillary dissection In breast cancer with clinically negative lymph nodes. Lancet. 1997;349(9069):1864-7.

Guenther JM, Krishnamoorthy M, Ton LR. Sentinel Lymphadenectomy for breast cancer in a community managed care setting. Cancer J Sci Am. 1997;3(6):336-40.

Simmons R, Thovarajah S, Brennon MB Christos P, Osborne M. Methylene blue dye as an alternative to Isosulfan blue dye for sentinel lymph node localization. Ann Surg Oncol. 2003;10(3):242-7.